Semarion
Paul manages the Board and guides the Executive Team on partnering and business development. He is Chief Business Officer at Mission Therapeutics. Paul has been involved in several trade sales and has executed over $4.5B worth of outlicensing partnerships including the hepatitis C protease inhibitor, Olysio.
This person is not in the org chart
This person is not in any teams